Phanes Therapeutics’ PT217 granted Fast Track Designation by the FDA
Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received FDA Fast Track designation for treating extensive-stage small cell lung cancer (ES-SCLC). PT217, also granted orphan drug status in 2022, is in Phase I trials for SCLC, LCNEC, and EP-NECs, aiming to improve survival rates in these aggressive cancers.
Related Clinical Trials
Reference News
Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received FDA Fast Track designation for treating extensive-stage small cell lung cancer (ES-SCLC). PT217, also granted orphan drug status in 2022, is in Phase I trials for SCLC, LCNEC, and EP-NECs, aiming to improve survival rates in these aggressive cancers.
Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received FDA Fast Track designation for treating extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy. PT217, also granted orphan drug status in 2022, is in Phase I trials for SCLC, LCNEC, and EP-NECs, aiming to improve survival rates for these aggressive cancers.
Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received FDA Fast Track designation for treating extensive-stage small cell lung cancer (ES-SCLC). PT217, also granted orphan drug status in 2022, is in Phase I trials for SCLC, LCNEC, and EP-NECs, aiming to improve survival rates in these aggressive cancers.
The FDA granted fast track designation to PT217 for treating ES-SCLC post-platinum-based chemotherapy. PT217, a bispecific antibody targeting DLL3 and CD47, is in phase 1 trials for SCLC, LC-NEC, and EP-NEC, aiming to enhance antitumor activity through immune system activation. The SKYBRIDGE trial evaluates its safety and efficacy in advanced refractory cancers.